Innate Pharma

IPHA

Market cap $132M

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the D. Boral Capital Global Conference.

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination with durvalumab and platinum-based chemotherapy in resectable non-small cell lung cancer (NSCLC) will be presented in one of the Clinical Trials Plenary Sessions at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22.

MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of April 9, 2026.

MARSEILLE, France--(BUSINESS WIRE)-- #Actionnaires--Innate Pharma to hold its annual general meeting of shareholders on May 21, 2026.

MARSEILLE, France--(BUSINESS WIRE)-- #AACR--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), announced today that Yannis Morel, Chief Operating Officer, will present at the AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients. Yannis Morel will present in the Showcase Session 2 on Thursday, April 16, 2026, at 6:10 PM PDT, at the San Diego Convention Center in San Diego, California. The AACR Oncology Industry Partnering Event is a.

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the Kempen Life Sciences conference.

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) And 2025 Form 20-f Annual Report.

Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its business update and consolidated financial results for the year ending December 31, 2025. The consolidated financial statements are attached to this press release. “2025 has been a year of strong execution across our portfolio. With the TELLOMAK-3 design finalized and FDA clearance in hand, lacutamab is planned for confirmatory Phase 3 initiati.

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma announces conference call and webcast for full year 2025 financial results.